Metastatic or Recurrent Head and Neck Squamous Cell Cancer Clinical Trial
— ELANFITOfficial title:
Phase II Multicenter Trial Evaluating First Line Carboplatin, 5-Fluorouracil and Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer, Aged 70 and Over, Ranked as Fit (no Frailty) by Geriatric Assessment
| Verified date | August 2022 |
| Source | Groupe Oncologie Radiotherapie Tete et Cou |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The aim of the trial is to evaluate the clinical benefit (efficacy, safety, preservation of autonomy) of cetuximab-carboplatin-5FU combination as first line treatment of recurrent or metastatic head and neck squamous cell carcinoma in patients over 70 years without frailty (after geriatric assessment).
| Status | Completed |
| Enrollment | 85 |
| Est. completion date | May 26, 2020 |
| Est. primary completion date | April 2020 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 70 Years and older |
| Eligibility | Inclusion Criteria: - Age greater than or equal to 70 years - patient enrolled in ELAN-ONVOCAL study and evaluated as fit (harmonious aging) by GERICO screening method for geriatric frailty - life expectancy superior to 12 weeks - creatinin clearance > ou equal to 50ml/mn calculated using Modification of Diet in Renal Disease (MDRD) formula - hematologic function : absolute neutrophil count > 1.5 x 10^9/l, platelets > 100 x 10^9/l, hemoglobin > 9,5 g/dl - liver function : total bilirubin inferior to 1,25 x Upper limit of normal (ULN), SGOT/SGPT inferior to 5 x ULN, PAL inferior to 5 x ULN - PS < 2 The disease: - histologically proven head and neck squamous cell carcinomas - recurrent or metastatic. Visceral metastases or locoregional recurrence unsuitable for curative locoregional treatment: unsuitable for primitive tumor surgery due to local extension (evidently authorized for lymph nodes) and unsuitable for radiotherapy for primitive tumor (or already performed) due to metastatic dissemination and the absence of indication for re-irradiation of primitive tumor. - Presence of at least one measurable lesion (defined by RECIST criteria) by CT scan or IRM - asymptomatic cerebral metastases authorized General: - signed Informed Consent Form - affiliated to the French social security system (or a beneficiary of this system) according to the provisions of the law of 9 August 2004 Exclusion Criteria: - Previous systemic chemotherapy, except for chemotherapy as part of multimodal treatment for locally advanced cancer completed more than 6 months prior to study enrollment - Known contraindication specific to one of study treatments (particularly cardiac for 5FU) - Known dihydropyrimidine dehydrogenase deficiency (DPD deficiency). - Patients considered as "unfit " (fragile) by GERICO screening method for geriatric frailty - Irradiation within 4 weeks prior to study enrollment. - Nasopharyngeal, rhinopharyngeal or maxillary sinus carcinoma. - Presence of infection (infection requiring intravenous antibiotics), including tuberculosis and HIV infection (human immunodeficiency virus). - Concomitant treatment with other antitumor immunotherapy or hormonal therapy. - Other antitumor concomitant therapies. - Prior treatment with EGFR-targeted therapy (epidermal growth factor receptor). - Treatment with one of study drugs within 30 days prior to study enrollment. - Presence of documented symptomatic brain or leptomeningeal metastases - Clinically significant coronaropathy or antecedent myocardial infarction within 12 months prior to study enrollment or high-risk uncontrolled arrhythmias or uncontrolled heart failure. - Medically uncontrolled arterial hypertension - Other prior or concomitant cancer, with exception for carcinoma in situ of the uterine cervix, or for cutaneous basal cell carcinoma within 5 years prior to study enrollment. - Presence of medical or physiological factors susceptible to modify patient compliance with study protocol and follow-up or Informed Consent Form signing. - Known allergy or hypersensibility to monoclonal antibodies (bevacizumab, cetuximab), or to other chemotherapies of the study or to their excipients |
| Country | Name | City | State |
|---|---|---|---|
| France | Hôpital de la Dracénie | Draguignan | |
| France | Institut Gustave Roussy | Villejuif |
| Lead Sponsor | Collaborator |
|---|---|
| Groupe Oncologie Radiotherapie Tete et Cou | Gustave Roussy, Cancer Campus, Grand Paris |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Objective response and acute toxicity | Objective tumor response at 12 weeks, safety (no grade 3, 4, 5 toxicities) and preservation of geriatric autonomy (absence of 2 or more points decrease on the Activities of Daily Living (ADL) scale) 1 month after the end of chemotherapy | 1 month after the end of chemotherapy | |
| Secondary | Best objective tumor response | Best objective tumor response during treatment | 6 weeks after the end of treatment | |
| Secondary | Overall survival | Overall survival | 1 year after the end of treatment | |
| Secondary | progression free survival | progression free survival | 1 year after the end of treatment | |
| Secondary | Duration of response under cetuximab maintenance therapy | Duration of response under cetuximab maintenance therapy | 1 year after the end of maintenance | |
| Secondary | Toxicity of cetuximab maintenance therapy | Toxicity of cetuximab maintenance therapy | 3 months after the end of maintenance | |
| Secondary | autonomy | Autonomy assessed by ADL and IADL scales during treatment and until 1 month after the end of treatment | 1 month after the end of treatment | |
| Secondary | Health related quality of life | Quality of life assessed by EORTC QLQ-C30 and QLQ-HN35 questionnaires | 1 month after the end of chemotherapy |